

1 DANIEL L. WARSHAW (Bar No. 185365)
dwarshaw@pswlaw.com
2 BOBBY POUYA (Bar No. 245527)
bpouya@pswlaw.com
3 MATTHEW A. PEARSON (Bar No. 291484)
mapearson@pswlaw.com
4 ALEXANDER R. SAFYAN (Bar No. 277856)
asafyan@pswlaw.com
5 **PEARSON, SIMON & WARSHAW, LLP**
6 15165 Ventura Boulevard, Suite 400
7 Sherman Oaks, California 91403
8 Telephone: (818) 788-8300
9 Facsimile: (818) 788-8104

10 Attorneys for Plaintiff James Eashoo,
11 individually and on behalf of all others
12 similarly situated

13 **UNITED STATES DISTRICT COURT**
14 **CENTRAL DISTRICT OF CALIFORNIA**
15

16 JAMES EASHOO, individually and on
17 behalf of all others similarly situated,

18 Plaintiff,

19 vs.
20

21 IOVATE HEALTH SCIENCES U.S.A.,
22 INC.,

23 Defendant.
24
25
26
27
28

CASE NO. 2:15-cv-01726-BRO-PJW
(Assigned to the Honorable Beverly
Reid O'Connell)

CLASS ACTION

**NOTICE OF MOTION AND
MOTION FOR PRELIMINARY
APPROVAL OF CLASS ACTION
SETTLEMENT**

Date: November 9, 2015
Time: 1:30 p.m.
Crtrm: 14 - Spring St. Floor

TO ALL PARTIES AND THEIR RESPECTIVE ATTORNEYS OF RECORD:

PLEASE TAKE NOTICE that on November 9, 2015, at 1:30 p.m. or as soon thereafter as the matter may be heard in the Courtroom of the Honorable Beverly Reid O'Connell, United States District Court, Central District of California, Central Division, Plaintiff James Eashoo will and hereby does move the Court, pursuant to Federal Rule of Civil Procedure 23(e), for the entry of an Order:

1. Preliminarily approving the Settlement Agreement between Plaintiff James Eashoo and Defendant Iovate Health Sciences U.S.A., Inc.;
2. Directing notice of the proposed settlement to the Class; and
3. Setting a schedule for the final approval process.

The grounds for this motion are that the proposed settlement is within the necessary range of reasonableness to justify granting preliminary approval.

This motion is based upon this Notice of Motion and Motion for Preliminary Approval of Class Action Settlement, the Declaration of Daniel L. Warshaw, the pleading and papers on file in this action, and such oral and documentary evidence as may be presented at the hearing on this motion.

DATED: October 9, 2015

PEARSON, SIMON & WARSHAW, LLP
DANIEL L. WARSHAW
BOBBY POUYA
MATTHEW A. PEARSON
ALEXANDER R. SAFYAN

By: /s/ Daniel L. Warshaw
DANIEL L. WARSHAW
Attorneys for Plaintiff James Eashoo,
individually and on behalf of all others

PEARSON, SIMON & WARSHAW, LLP
15165 VENTURA BOULEVARD, SUITE 400
SHERMAN OAKS, CALIFORNIA 91403

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

TABLE OF CONTENTS

Page

MEMORANDUM OF POINTS AND AUTHORITIES..... 1

I. INTRODUCTION 1

II. FACTUAL AND PROCEDURAL HISTORY..... 2

III. SUMMARY OF THE SETTLEMENT..... 4

 A. Class Member Relief..... 5

 1. Monetary Relief 5

 2. Injunctive Relief 5

 B. Narrowly Tailored Release 6

 C. Cost of Administration and Class Notice 6

IV. THE COURT SHOULD PRELIMINARILY APPROVE THE SETTLEMENT 6

 A. Standard for Preliminary Approval..... 6

 B. The Settlement Provides Substantial Relief to the Class and is Well Within the Necessary Range of Reasonableness 8

 1. The Strength of Plaintiff’s Case Compared to the Risk, Expense, Complexity, and Likely Duration of Further Litigation..... 8

 2. The Amount Offered in Settlement 10

 3. The Risk of Maintaining Class Action Status Through Trial..... 11

 4. The Extent of Discovery Completed and the Stage of the Proceedings..... 11

 5. The Experience and Views of Counsel..... 12

V. THE COURT SHOULD CERTIFY A SETTLEMENT CLASS FOR SETTLEMENT PURPOSES 13

 A. The Requirements of Rule 23(a) Are Satisfied..... 13

 1. Numerosity..... 14

 2. Commonality 14

1	3. Typicality	15
2	4. Adequacy of Representation.....	15
3	B. The Requirements of Rule 23(b)(3) Are Satisfied.....	16
4	VI. THE SETTLEMENT PROVIDES PROPER NOTICE TO THE CLASS.....	17
5	VII. THE COURT SHOULD SET A FINAL APPROVAL HEARING SCHEDULE	19
6	VIII. ATTORNEYS’ FEES AND COSTS AND ENHANCEMENT AWARDS.....	20
7	IX. CONCLUSION	21
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		

PEARSON, SIMON & WARSHAW, LLP
15165 VENTURA BOULEVARD, SUITE 400
SHERMAN OAKS, CALIFORNIA 91403

PEARSON, SIMON & WARSHAW, LLP
15165 VENTURA BOULEVARD, SUITE 400
SHERMAN OAKS, CALIFORNIA 91403

TABLE OF AUTHORTIES

		<u>Page</u>
		<u>Page(s)</u>
1	CASES	
2		
3		
4	<i>Amchem Prods., Inc. v. Windsor</i> ,	
5	521 U.S. 591 (1997)	17, 13
6		
7	<i>Churchill Vill., L.L.C. v. Gen. Elec.</i> ,	
8	361 F.3d 566 (9th Cir. 2004)	6, 7
9		
10	<i>Class Plaintiffs v. City of Seattle</i> ,	
11	955 F.2d 1268 (9th Cir. 1992)	6
12		
13	<i>Hanlon v. Chrysler Corp.</i> ,	
14	150 F.3d 1011 (9th Cir. 1998)	7, 15
15		
16	<i>Hanon v. Dataproducts Corp.</i> ,	
17	976 F.2d 497 (9th Cir. 1992)	15
18		
19	<i>In re Abbott Labs. Norvir Anti-trust Litig.</i> ,	
20	Case Nos. C 04-1511 CW, C 04-4203 CW, 2007 WL 1689899, (N.D. Cal.	
21	June 11, 2007).....	14
22		
23	<i>In re Mercury Interactive Corp. Sec. Litig.</i> ,	
24	618 F.3d 988 (9th Cir. 2010)	20
25		
26	<i>In re Syncor ERISA Litig.</i> ,	
27	516 F.3d 1095 (9th Cir. 2008)	6
28		
	<i>In re Tableware Antitrust Litig.</i> ,	
	484 F.Supp.2d 1078 (N.D. Cal. 2007).....	6, 17
	<i>Ivie v. Kraft Foods Global, Inc.</i> ,	
	2015 WL 183910, (N.D. Cal. Jan. 14, 2015)	9, 10
	<i>Mullane v. Cen. Hanover Bank & Trust Co.</i> ,	
	229 U.S. 306 (1950)	17
	<i>Radcliffe v. Experian Info. Solutions, Inc.</i> ,	
	715 F.3d 1157 (9th Cir. 2013)	20

1 *Torrison v. Tucson Elec. Power Co.*,
2 8 F.3d 1370 (9th Cir. 1993) 7

3 *Vasquez v. Coast Valley Roofing, Inc.*,
4 670 F.Supp.2d 1114 (E.D. Cal. 2009) 7

5 *Wal-Mart Stores, Inc. v. Dukes*,
6 131 S. Ct. 2541 (2011)..... 13, 14, 16

7 **STATUTES & RULES**

8 Cal. Bus. & Prof. Code §§ 17200 *et seq.* 2, 3

9 Cal. Bus. & Prof. Code §§ 17500 *et seq.* 2

10 Cal. Civ. Code § 1781..... 17

11 Cal. Civ. Code §§ 1770 *et seq.* 2

12 Fed. R. Civ. P. 23(a) 13, 14, 16

13 Fed. R. Civ. P. 23(b) 13, 16

14 Fed. R. Civ. P. 23(c)(2)(B) 16

15 Fed. R. Civ. P. 23(e) 6

16 Fed. R. Civ. P. 26..... 3, 12

17 Fed. R. Civ. P. 30(b)(6) 3, 12

18 Magnuson-Moss Warranty Act, 15 U.S.C. §§ 2301, *et seq.* 2

19

20

21

22

23

24

25

26

27

28

PEARSON, SIMON & WARSHAW, LLP
15165 VENTURA BOULEVARD, SUITE 400
SHERMAN OAKS, CALIFORNIA 91403

MEMORANDUM OF POINTS AND AUTHORITIES

I. INTRODUCTION

This class action is centered on allegations that Defendant Iovate Health Sciences U.S.A., Inc. (“Iovate”) “spiked” its protein supplements with non-protein compounds to artificially inflate the claimed amount of protein contained therein. Rather than litigate this case through class certification and trial, and face the uncertainties that come therewith, Plaintiff James Eashoo (“Plaintiff” or “Eashoo”) and Iovate engaged in arm’s-length settlement negotiations with the assistance of a respected and experienced neutral, the Honorable Dickran M. Tevrizian (Ret.). As a result of these settlement negotiations, Plaintiff has obtained a nationwide class action Settlement,¹ which provides substantial monetary and injunctive relief to purchasers of Iovate protein supplements and adequately remedies the harm alleged by Plaintiff.

The Settlement Agreement creates a \$2.5 million non-reversionary common fund in which Class Members can participate and obtain refunds for their eligible purchases in three ways: (1) filing a claim using receipts for a 100% refund of the amount(s) shown on the receipt for each Protein Product² up to \$300 per household; (2) filing a claim by submitting proof of purchase to redeem the suggested retail price for each Protein Product up to \$300 per household; or (3) filing a claim without any receipt or proof of purchase to receive \$10.00 per Protein Product up to

¹ All capitalized terms herein shall have the definitions set forth in the Settlement Agreement unless otherwise stated. The Settlement Agreement is attached to the Declaration of Daniel L. Warshaw as Exh. 1.

² The term “Protein Products” is defined in the Settlement Agreement and herein as any of the protein supplements distributed by Defendant under any brand name including MuscleTech, Six Star, Epic, or fuel:one during the Class Period. (Settlement Agreement § 1.32.)

1 \$50.00 per household.

2 Additionally, the Settlement provides for injunctive relief that requires Iovate
3 to accurately test, measure and disclose the amount of protein in the Protein
4 Products by eliminating amino acids, creatine, and other nitrogen producing non-
5 protein compounds from its protein calculations. This injunctive relief directly
6 addresses the allegations in this lawsuit and ensures that consumers will be able to
7 make informed purchasing decisions regarding the Protein Products.

8 When weighed against the risks, costs, delay, and uncertainties of continuing
9 the litigation, the Settlement constitutes an excellent result that is fair, adequate, and
10 reasonable, and comports with all of the criteria for preliminary approval.
11 Furthermore, the notice plan contemplated by the Settlement Agreement and
12 detailed herein complies with the applicable law and is the best notice practicable
13 for this case. Accordingly, Plaintiff requests that the Court grant preliminary
14 approval to the proposed Settlement, direct distribution of notice to the Settlement
15 Class, and set a schedule for final approval of the Settlement.

16 **II. FACTUAL AND PROCEDURAL HISTORY**

17 Plaintiff originally filed this class action lawsuit on March 10, 2015. (Dkt. 1
18 and Declaration of Daniel L. Warshaw (“Warshaw Decl.”), ¶ 5.) Plaintiff thereafter
19 filed the operative First Amended Complaint (“FAC”) on April 10, 2015. (Dkt. 16.)
20 The FAC alleges causes of action on behalf of Plaintiff and a putative nationwide
21 class of purchasers of Iovate Protein Products since March 10, 2011 for: (1)
22 violation of the California Consumers Legal Remedies Act, Cal. Civ. Code §§ 1770
23 *et seq.* (“CLRA”); (2) breach of express warranty; (3) negligent misrepresentation;
24 (4) violations of California’s false advertising law, Cal. Bus. & Prof. Code §§ 17500
25 *et seq.* (“FAL”); (5) violation of the Magnuson-Moss Warranty Act, 15 U.S.C. §§
26 2301, *et seq.*; and (6) violation of California’s unfair competition law, Cal. Bus. &
27 Prof. Code §§ 17200 *et seq.* (“UCL”).

28 The crux of Plaintiff’s lawsuit is that Iovate engaged in a practice commonly

1 referred to as “protein spiking,” whereby it added creatine, amino acids, and other
2 non-protein ingredients in the Protein Products that falsely registered as proteins
3 under certain nitrogen based protein testing methods. (Dkt. 15, ¶¶ 26-29.) Plaintiff
4 alleged that by counting these non-protein ingredients as proteins, Iovate misled
5 consumers by artificially increasing the claimed protein content of the Protein
6 Products. Plaintiff further alleged that Iovate misrepresented the qualities and
7 benefits of the Protein Products by double counting these amino acids and non-
8 protein compounds towards the amount of protein, and separately claiming that the
9 products contain these compounds “*in addition* to proteins.” (*Id.*, ¶ 30.) Plaintiff
10 alleged that as a result of Iovate’s material misrepresentations, Plaintiff and other
11 similarly situated consumers were induced into purchasing or paying more for
12 Iovate’s Protein Products than they otherwise would have.

13 The parties exchanged Rule 26 initial disclosures on April 13, 2015 and
14 engaged in pre-certification discovery. In response to Plaintiff’s discovery requests,
15 Iovate has produced over 1,000 pages of documents, relating to the testing,
16 formulation, advertising, promotion, sales, protein content, and protein calculation
17 of the Protein Products. (Warshaw Decl., ¶ 6.) Plaintiff also took the deposition of
18 Iovate’s Rule 30(b)(6) witness, Derek Smith, regarding these same subjects on April
19 30, 2015. (*Id.*, ¶ 7.) Iovate took the deposition of Plaintiff James Eashoo on May 5,
20 2015. (*Id.*, ¶ 8.)

21 Iovate filed a Motion to Dismiss on May 11, 2015. (Dkt. 32 and Warshaw
22 Decl., ¶ 9.) After the Motion to Dismiss was filed, the parties continued to meet
23 and confer regarding the arguments raised in the Motion. (Warshaw Decl., ¶ 9.) As
24 a result of these discussions, and in an effort to narrow the issues before the Court,
25 on June 7, 2015, Iovate withdrew its initial Motion to Dismiss. (Dkt. 36 and
26 Warshaw Decl., ¶ 10.) On June 19, 2015, Iovate filed a new Motion to Dismiss,
27 arguing that Plaintiff’s claims are preempted by the regulations of the Federal Food,
28 Drug and Cosmetics Act (“FDCA”) relating to the calculation of the protein content

1 in dietary supplements. (Dkt. 38.) Plaintiff filed his opposition to Iovate's second
2 Motion to Dismiss on July 27, 2015, (Dkt. 39 and Warshaw Decl., ¶ 11), and
3 Defendant filed its Reply on August 3, 2015. (Dkt. 40.) Defendant's Motion to
4 Dismiss was scheduled to be heard on August 17, 2015. (Dkt. 39 & Warshaw Decl.,
5 ¶ 11.)

6 In May 2015, the parties attended an initial mediation session with Judge
7 Tevrizian. (Warshaw Decl., ¶ 12.) This initial mediation did not result in a
8 successful resolution of the case. (*Id.*) However, the parties, with the assistance of
9 Judge Tevrizian, continued to engage in settlement talks. (*See id.*, ¶ 13.) These
10 settlement discussions were robust and hotly contested, and at times it appeared that
11 a Settlement could not be achieved. (*See id.*)

12 Under Judge Tevrizian's supervision, the parties ultimately reached
13 agreement on the essential terms of a settlement with a full and complete
14 understanding of the relevant facts and circumstances surrounding this litigation.
15 (*See Id.*) The parties filed their Notice of Settlement on August 12, 2015. (Dkt. 41
16 and Warshaw Decl., ¶ 15.) The parties did not discuss or reach any agreement on
17 attorneys' fees, costs, or incentive awards prior to finalizing the terms of the relief to
18 the Class Members. (Warshaw Decl., ¶ 14.) The parties finalized the Settlement
19 Agreement on September 21, 2015. (*See* Settlement Agreement, Warshaw Decl., at
20 Exh. 1.)

21 **III. SUMMARY OF THE SETTLEMENT**

22 The Settlement Agreement provides for a Non-Reversionary Common Fund
23 that will be used to pay Class Member claims, administration costs, attorneys' fees,
24 and expenses in this litigation. Under the Settlement Agreement, participating Class
25 Members will receive a **one hundred percent** refund up to \$300 if they submit
26 receipts or proof of purchase, or up to \$50 without any receipts or proof of purchase.
27 The Settlement Agreement also provides significant injunctive relief in the form of
28 modifications to the labels of Iovate's Protein Products. The material terms of the

1 Settlement Agreement are set forth below.

2 **A. Class Member Relief**

3 **1. Monetary Relief**

4 Pursuant to the Settlement Agreement, Iovate will provide a refund to Class
5 Members who submit a timely and valid Claim Form. Settlement Class Members
6 will be eligible to obtain monetary relief either with or without proof of purchase
7 paid from the Settlement Fund. The Settlement allows Class Members to choose one
8 of the following claim methods: (1) Settlement Class Members who submit valid
9 receipts showing purchases of one or more Protein Products will receive a 100%
10 refund of the amount(s) shown on the Receipt(s), up to \$300 per household; (2)
11 Settlement Class Members who submit valid proof of purchase other than receipts
12 (e.g. Protein Product labels, SKUs, etc.), will receive a refund for the suggested
13 retail price of each Protein Product, up to \$300 per household; or (3) Settlement
14 Class Members who do not provide a receipt or proof of purchase, but affirm under
15 penalty of perjury that they purchased a Protein Product during the Class Period,
16 will receive \$10.00 per Protein Product, up to \$50.00 per household. (*See*
17 Settlement Agreement § 4.3.2.)

18 The Settlement Fund created by the Settlement Agreement is designed to
19 maximize the recovery of Class Members. As such, any amounts remaining in the
20 fund after all claims have been paid will be distributed to Class Members who made
21 valid claims. (*See* Settlement Agreement § 4.3.6.) Under no circumstance will any
22 funds revert back to Iovate. (*Id.*)

23 **2. Injunctive Relief**

24 The Settlement also requires Iovate to provide injunctive relief to the Class by
25 modifying the testing, labeling, packaging, and advertising for its Protein Products
26 to insure that the nitrogen content attributed to amino acids, creatine, and other non-
27 protein substances therein are not included in the protein calculation. (*See*
28 Settlement Agreement § 4.1.1.) This injunctive relief is significant because it

1 directly addresses and remedies the central allegation in Plaintiff’s lawsuit—that
2 nitrogen from amino acids, creatine, and other non-protein substances artificially
3 inflated the amount of claimed protein in the Protein Products.

4 **B. Narrowly Tailored Release**

5 The Settlement Agreement contains a narrowly tailored Class Member release
6 that is specifically limited to the claims arising out of or relating to the Complaint
7 during the Class Period. (*Id.* § 6.1.) As set forth herein, these allegations are
8 limited to Plaintiff’s claims that Iovate misrepresented and artificially inflated the
9 true protein content of the Protein Products.

10 **C. Cost of Administration and Class Notice**

11 Under the Settlement Agreement, all costs and expenses of administering the
12 Settlement and providing Notice in accordance with the Preliminary Approval Order
13 shall be distributed from the Non-Reversionary Common Fund. (Settlement
14 Agreement § 5.1.1.) The parties have selected Rust Consulting, Inc. (“Rust”) as the
15 claims administrator, and Kinsella Media, Inc. (“Kinsella”) as the notice provider.

16 **IV. THE COURT SHOULD PRELIMINARILY APPROVE THE**
17 **SETTLEMENT**

18 **A. Standard for Preliminary Approval**

19 Rule 23(e) requires court approval of any settlement of claims of a settlement
20 class. It is well-settled that there is “a strong judicial policy that favors settlements,
21 particularly where complex class action litigation is concerned.” *Class Plaintiffs v.*
22 *City of Seattle*, 955 F.2d 1268, 1276 (9th Cir. 1992); *see also Churchill Vill., L.L.C.*
23 *v. Gen. Elec.*, 361 F.3d 566, 576 (9th Cir. 2004); *In re Syncor ERISA Litig.*, 516
24 F.3d 1095, 1101 (9th Cir. 2008).

25 To grant preliminary approval of a class action settlement, a court need only
26 find that the settlement is within “the range of reasonableness” to justify publishing
27 and sending notice of the settlement to Class Members and scheduling final
28 approval proceedings. *See In re Tableware Antitrust Litig.*, 484 F.Supp.2d 1078,

1 1079-80 (N.D. Cal. 2007); Newberg on Class Actions § 13:15 (5th ed.). Preliminary
2 approval should be granted where “the proposed settlement appears to be the
3 product of serious, informed, non-collusive negotiations, has no obvious
4 deficiencies, does not improperly grant preferential treatment to class
5 representatives or segments of the class, and falls within the range of possible
6 approval.” *Vasquez v. Coast Valley Roofing, Inc.*, 670 F.Supp.2d 1114, 1125 (E.D.
7 Cal. 2009).

8 The approval of a proposed class action settlement “is committed to the sound
9 discretion of the trial judge.” *Hanlon v. Chrysler Corp.*, 150 F.3d 1011, 1026 (9th
10 Cir. 1998). In exercising this discretion, however, courts must give “proper
11 deference to the private consensual decision of the parties” because “the court’s
12 intrusion upon what is otherwise a private consensual agreement negotiated between
13 the parties to a lawsuit must be limited to the extent necessary to reach a reasoned
14 judgment that the agreement is not the product of fraud or overreaching by, or
15 collusion between, the negotiating parties, and the settlement, taken as a whole, is
16 fair, reasonable and adequate to all concerned.” *Id.* at 1027.

17 In making a preliminary determination of the fairness, reasonableness, and
18 adequacy of a class action settlement, the trial court must balance a number of
19 factors, including:

20 (1) the strength of the plaintiff’s case; (2) the risk, expense, complexity,
21 and likely duration of further litigation; (3) the risk of maintaining class
22 action status throughout the trial; (4) the amount offered in settlement;
23 (5) the extent of discovery completed and the stage of the proceedings;
24 (6) the experience and views of counsel; (7) the presence of a
governmental participant; and (8) the reaction of the Class Members to
the proposed settlement.

25 *Churchill Vill.*, 361 F.3d at 575; *see also Torrissi v. Tucson Elec. Power Co.*, 8 F.3d
26 1370, 1375 (9th Cir. 1993). At the preliminary approval stage, a final analysis of
27 the settlement’s merits is not warranted. Instead, a more detailed assessment is
28

1 reserved for final approval, after class notice has been sent and Class Members have
2 had the opportunity to object to, or opt out of, the settlement. *See* Moore’s Fed.
3 Prac. § 23.165 (3d ed. 2009).

4 **B. The Settlement Provides Substantial Relief to the Class and**
5 **is Well Within the Necessary Range of Reasonableness**

6 The Settlement in this case is fair, reasonable, and adequate and should be
7 approved by the Court because it provides substantial monetary relief and injunctive
8 relief to Settlement Class Members. Significantly, the Settlement Agreement will
9 provide up to \$300 for claimants with proof of purchase and up to \$50 for claimants
10 without proof of purchase, and requires Iovate to modify its testing protocols and
11 procedures to ensure that creatine, amino acids, and other non-protein compounds
12 are not counted towards the protein calculation. As detailed below, the factors to be
13 considered by the Court weigh heavily in favor of preliminary approval, because the
14 Settlement Agreement adequately remedies the false advertising claims alleged by
15 Plaintiff in this class action lawsuit.

16 **1. The Strength of Plaintiff’s Case Compared to the Risk,**
17 **Expense, Complexity, and Likely Duration of Further**
18 **Litigation**

19 Although risks and expenses apply to any lawsuit, these elements were
20 significant in this case and weigh strongly in favor of approving the Settlement. As
21 set forth above, Plaintiff’s lawsuit alleges that Iovate misled consumers because the
22 Protein Products contained less protein than the represented amount. The basis for
23 Plaintiff’s lawsuit was that Iovate added or “spiked” its Protein Products with
24 creatine, amino acids, and other nitrogen based non-protein additives, which falsely
25 registered as proteins under certain testing methods.

26 Iovate vigorously defended its protein testing methodology and asserted that
27 Plaintiff’s claims were without merit. Furthermore, Iovate brought a Motion to
28

1 Dismiss on grounds that its protein testing methods and procedures complied with
2 federal law under the FDCA. Defendant argued that Plaintiff's lawsuit asserting
3 violations of California law were preempted by the FDCA and could not proceed
4 past the pleading stage. Although Plaintiff believes that he would have defeated
5 Iovate's Motion to Dismiss, there was no guarantee that Plaintiff would have
6 overcome the preemption argument. Even if Plaintiff did defeat Iovate's Motion to
7 Dismiss, Iovate was likely going to assert preemption as a defense to class
8 certification and trial.

9 If the parties did not reach a settlement, Iovate would have undoubtedly
10 asserted additional legal and factual defenses at class certification, summary
11 judgment, and trial. Thus, there was no guarantee that Plaintiff would have been
12 able to certify a nationwide class and obtain any recovery on behalf of the Class
13 Members. Even if Plaintiff prevailed at class certification and trial, it was uncertain
14 whether he could recover damages in the full amount of the purchase price of the
15 Protein Products, as permitted under the Settlement. *See Ivie v. Kraft Foods Global,*
16 *Inc.*, 2015 WL 183910, at * 2 (N.D. Cal. Jan. 14, 2015) (advocating for the price
17 premium model for damages rather than awarding the full purchase price of the
18 misbranded products). As such, in the absence of the Settlement, Plaintiff would
19 have faced significant litigation risks and no substantial prospect of obtaining a
20 better result on behalf of the Class Members.

21 Plaintiff would have also incurred substantial litigation expenses in order to
22 litigate this case through class certification and trial. In addition to ordinary
23 litigation expenses (e.g. filing fees, travel, court reporters, etc.), Plaintiff would have
24 had to incur expert fees and conduct substantial expert discovery in order to
25 demonstrate the Protein Products contained less protein than the amount claimed by
26 Iovate, and Plaintiff's claims could be litigated through trial on a class-wide basis.

27 Finally, since this case was in its early stages and the Court had not yet set a
28 trial date or pre-trial schedule, Plaintiff would have had to litigate this case for a

lengthy and unknown duration of time in order to prevail at class certification and trial. A successful result at trial may have also resulted in a post-trial appeal by Iovate. Therefore, this Settlement provides complete relief to the Class without the delay and risk of further litigation.

In light of the above, the litigation risks, expense, complexity, and duration of further litigation weigh heavily in favor of granting preliminary approval, especially when weighed against the substantial monetary and injunctive relief provided by the Settlement.

2. The Amount Offered in Settlement

The benefits offered by the Settlement Agreement also weigh heavily in favor of preliminary approval. As detailed above, the Settlement Agreement creates a \$2.5 million Non-Reversionary Common Fund that provides substantial monetary relief to the Class Members. Specifically, claimants can obtain a 100% refund up to \$300 if they provide receipts or proof of purchase of one or more of Iovate's Protein Products. (Settlement Agreement §§ 4.3.2.1, 4.3.2.2.) This relief is arguably more than claimants would have been able to obtain at trial, because it refunds the full purchase price of the Protein Products, rather than limiting damages to the price premium attributable to Iovate's alleged misrepresentations. *See Ivie*, 2015 WL 183910, at * 2.

The Settlement Agreement also allows Class Members without any proof of purchase to receive \$10 per Protein Product, up to \$50 per household, if they swear or affirm under penalty of perjury that they purchased one or more Iovate Protein Products during the Class Period. (Settlement Agreement § 4.3.2.3.) This option for recovery is significant because it ensures that Class Members can participate in a manner that is convenient and does not require them to maintain or submit proof of past purchases.

Class Members will also benefit from injunctive relief that requires Iovate to eliminate nitrogen attributed to amino acids, creatine, and other non-protein

1 ingredients, from the amount of protein claimed in the Protein Products. (Settlement
2 Agreement § 4.1.1.) This injunctive relief specifically remedies the
3 misrepresentations alleged in the FAC, and ensures that future consumers will make
4 informed decisions relating to the purchase of the Protein Products.

5 When viewed in light of the risks and costs of further litigation, these
6 remedies constitute an exceptional result for the Class and justify granting
7 preliminary approval of the Settlement.

8 **3. The Risk of Maintaining Class Action Status Through Trial**

9 As set out more fully below, Plaintiff submits that this action could be
10 properly maintained as a class action. However, Iovate would have undoubtedly
11 vigorously opposed class certification, and there was no guarantee that Plaintiff
12 would be able to certify the Class and maintain class action status through trial.
13 These arguments asserted by Iovate in opposition to class certification would have
14 likely included attacks on almost every factor for class certification, including
15 ascertainability, typicality, adequacy of representation, and the existence of common
16 issues. Defendant would have likely argued that common issues did not
17 predominate because of variations in damages and Class Members' reliance on the
18 alleged protein content misrepresentations. (*See* Dkt. 38, Motion to Dismiss, at p. 1
19 (discussing the purported benefits of the creatine and amino acids added to the
20 Protein Products.)) Plaintiff's ability to maintain class certification status through
21 trial may have also been impacted by an unforeseen intervening change in law.

22 Although Plaintiff is confident that this action could be certified as a class
23 action, the risk of maintaining class action status throughout trial weighs in favor of
24 preliminary approval.

25 **4. The Extent of Discovery Completed and the Stage of the**
26 **Proceedings**

27 Although the case is in its early stages, the parties have conducted sufficient
28 discovery to allow them to make an informed decision regarding the legal and

1 factual sufficiency of the Settlement Agreement. (Warshaw Decl., ¶ 16.) Prior to
2 filing this lawsuit, Plaintiff and his counsel conducted a thorough investigation into
3 the facts of the case, including conducting independent testing of the Protein
4 Products. (*Id.*, ¶ 4.) After Plaintiff filed the lawsuit, the parties exchanged Rule 26
5 initial disclosures on April 13, 2015. (*Id.*, ¶ 6.) Plaintiff then served Iovate with a
6 Rule 30(b)(6) deposition notice and corresponding requests for production of
7 documents relating to the testing, formulation, advertising, promotion, sales, protein
8 content, and protein calculation of the Protein Products. (*Id.*, ¶ 6.) In response to
9 this discovery, Iovate produced, and Plaintiff reviewed, over 1,000 pages of
10 documents. (*Id.*) On April 30, 2015, Plaintiff took the deposition of Iovate's Rule
11 30(b)(6) witness, Derek Smith, regarding the core facts and allegations underlying
12 Plaintiff's claims. (*Id.*, ¶ 7.) Iovate then took the deposition of Plaintiff on May 5,
13 2015. (*Id.*, ¶ 8.)

14 The Settlement Agreement further requires Iovate to produce additional
15 confirmatory discovery regarding its sales revenue to verify the financial basis and
16 assumptions in the Settlement Agreement. (Settlement Agreement § 11.1.) In
17 addition to this formal discovery, the parties engaged in the informal exchange of
18 relevant facts and information through the mediation and settlement negotiation
19 process. (Warshaw Decl., ¶ 13.) This discovery and investigation provided the
20 parties and Judge Tevrizian with sufficient evidence and understanding of the facts
21 to evaluate the strengths and weaknesses of Plaintiff's claims, and make an
22 informed decision to enter into the Settlement Agreement. (*Id.*)

23 **5. The Experience and Views of Counsel**

24 Preliminary approval is further justified by the fact that Plaintiff and the Class
25 are represented by counsel from Pearson, Simon & Warshaw, LLP, who have
26 extensive experience in class action litigation, have negotiated numerous other class
27 action settlements, and have the ability to litigate this case on a class-wide basis
28 through trial if the parties failed to reach a fair settlement. (Warshaw Decl., ¶ 17.)

1 Class Counsel were satisfied with the Settlement Agreement only after conducting
2 intensive settlement negotiations with the assistance of Judge Tevrizian and
3 thorough investigation into the factual and legal issues raised in this case. (*Id.*, ¶¶
4 13, 16.) Class Counsel drew on their considerable experience and expertise in
5 negotiating and evaluating the Settlement, and in determining that the Settlement
6 Agreement was reasonable and provided substantive relief to the Class. (*See id.*, ¶¶
7 13, 17, 18, 23.)

8 **V. THE COURT SHOULD CERTIFY A SETTLEMENT CLASS**
9 **FOR SETTLEMENT PURPOSES**

10 Before granting preliminary approval of a settlement, the Court must
11 determine that the proposed Settlement Class is a proper class for settlement
12 purposes. Manual for Complex Litig. (4th ed. 2004) § 21.632; *Amchem Prods.*, 521
13 U.S. at 620. Certification is appropriate where the proposed class and the proposed
14 class representatives meet the four requirements of Rule 23(a)—numerosity,
15 commonality, typicality and adequacy of representation—and one of the three
16 requirements of Rule 23(b).

17 Here, Plaintiff seeks certification pursuant to Rules 23(a) and 23(b)(3) on
18 behalf of the Settlement Class, consisting of: “all persons in the United States of
19 America who purchased one or more of Defendant’s Protein Products at any time
20 during the [March 10, 2011 and the date of Preliminary Approval]. Excluded from
21 the Settlement Class are any officers, directors, or employees of Iovate, and the
22 immediate family member of any such person. Also excluded from the Settlement
23 Class is any judge who may preside over this case.” (Settlement Agreement §§ 1.9,
24 1.41.) For the reasons set forth below, all of the required elements of class
25 certification are satisfied.

26 **A. The Requirements of Rule 23(a) Are Satisfied**

27 “Rule 23(a) ensures that the named plaintiffs are appropriate representatives
28 of the class whose claims they wish to litigate.” *Wal-Mart Stores, Inc. v. Dukes*, 131

1 S. Ct. 2541, 2550 (2011). Under Rule 23(a), the party seeking certification must
2 demonstrate that:

3 (1) the class is so numerous that joinder of all members is impracticable;

4 (2) there are questions of law or fact common to the class;

5 (3) the claims or defenses of the representative parties are typical of the
6 claims or defenses of the class; and

7 (4) the representative parties will fairly and adequately protect the interests of
8 the class.

9 Fed. R. Civ. P. 23(a).

10 **1. Numerosity**

11 Rule 23(a)(1) requires that the class be “so numerous that joinder of all
12 members is impracticable.” Fed. R. Civ. P. 23(a)(1). “Where the exact size of the
13 class is unknown, but general knowledge and common sense indicate that it is large,
14 the numerosity requirement is satisfied.” *In re Abbott Labs. Norvir Anti-trust Litig.*,
15 Case Nos. C 04-1511 CW, C 04-4203 CW, 2007 WL 1689899, at *6 (N.D. Cal.
16 June 11, 2007). Here, there are at least thousands of Settlement Class Members,
17 which easily satisfies the numerosity requirement.

18 **2. Commonality**

19 Rule 23(a)(2) requires that there be “questions of law or fact common to the
20 class.” Fed. R. Civ. P. 23(a)(2). “Commonality requires the plaintiff to demonstrate
21 that the Class Members ‘have suffered the same injury.’” *Dukes*, 131 S. Ct. at 2551
22 (quoting *Gen. Tel. Co. of Sw. v. Falcon*, 457 U.S. 147, 157 (1982)). Class members’
23 claims “must depend upon a common contention . . . that is capable of classwide
24 resolution—which means that determination of its truth or falsity will resolve an
25 issue that is central to the validity of each one of the claims in one stroke.” *Id.*
26 “What matters to class certification . . . is not the raising of common ‘questions’—
27 even in droves—but, rather the capacity of a classwide proceeding to generate
28 common *answers* apt to drive the resolution of the litigation.” *Id.*

1 Here, the claims of all Class Members depend upon a common contention that
2 Iovate misrepresented the true amount of protein content in Iovate's Protein
3 Products by engaging in protein "spiking." All Class Members' claims are based
4 upon the same alleged conduct by Iovate, resulting in the litigation of common legal
5 issues. Further, the common questions of law and fact presented in this case could
6 only be efficiently resolved in a classwide proceeding that would generate common
7 answers to those questions.

8 **3. Typicality**

9 Rule 23(a)(3) is satisfied if "the claims or defenses of the representative
10 parties are typical of the claims or defenses of the class." Fed. R. Civ. P. 23(a)(3).
11 "Under the rule's permissive standards, representative claims are 'typical' if they are
12 reasonably co-extensive with those of absent Class Members; they need not be
13 substantially identical." *Hanlon*, 150 F.3d at 1020. "The test of typicality is
14 whether other members have the same or similar injury, whether the action is based
15 on conduct which is not unique to the named plaintiffs, and whether other Class
16 Members have been injured by the same course of conduct." *Hanon v.*
17 *Dataproducts Corp.*, 976 F.2d 497, 508 (9th Cir. 1992) (internal quotations
18 omitted).

19 Here, Plaintiff is a consumer who purchased the Protein Products as a dietary
20 supplement. Like similarly situated Class Members, Plaintiff relied on Iovate's
21 representations about the protein content and composition of its Protein Products in
22 making his purchase. Plaintiff's experience is not unique, but rather illustrative of
23 the experience of other Class Members. Accordingly, Plaintiff's claims are typical
24 of the claims of the Class.

25 **4. Adequacy of Representation**

26 Rule 23(a)(4) permits class certification only if "the representative parties will
27 fairly and adequately protect the interests of the class." Fed. R. Civ. P. 23(a)(4).
28 "This factor requires: (1) that the proposed representative plaintiffs do not have

1 conflicts of interest with the proposed class, and (2) that Plaintiffs are represented by
2 qualified and competent counsel.” *Dukes*, 603 F.3d at 614, *rev’d on other grounds*,
3 131 S. Ct. 2541 (2011) (quoting *Hanlon*, 150 F.3d at 1020).

4 Plaintiff does not have any conflicts of interest with the proposed Class.
5 Plaintiff’s claims are identical to the claims of other Class Members and arise from
6 the same conduct by Iovate. Plaintiff and other Class Members have suffered the
7 same injury, and Plaintiff seeks relief equally applicable and beneficial to the Class.
8 Further, Plaintiff is represented by qualified and competent counsel who have the
9 experience and resources necessary to vigorously pursue this action. (*See* Warshaw
10 Decl., ¶ 17 & Exh. 2 (“Firm Resume”).) Plaintiff and his counsel are able to fairly
11 and adequately represent the interests of the Class.

12 **B. The Requirements of Rule 23(b)(3) Are Satisfied**

13 In addition to meeting the prerequisites of Rule 23(a), a class action must
14 satisfy at least one of the three conditions of Rule 23(b). Plaintiff submits that the
15 Settlement Class satisfies Rule 23(b)(3). Under Rule 23(b)(3), a class action may be
16 maintained if: “[1] the court finds that the questions of law or fact common to Class
17 Members predominate over any questions affecting only individual members, and
18 [2] that a class action is superior to other available methods for fairly and efficiently
19 adjudicating the controversy.” Fed. R. Civ. P. 23(b)(3).

20 Here, common questions predominate over any individualized inquiries
21 relating to Class Members. Plaintiff’s claims are based upon the same conduct of
22 Iovate: misrepresenting the true protein content and composition of their Protein
23 Products. The class claims predominate over any evidential inquiry as the core
24 misrepresentation relates to the fundamental characteristics of the Protein Products,
25 the amount of protein contained therein. Consumers purchase Protein Products for
26 one reason, protein supplementation. The questions of law and fact surrounding this
27 ultimate issue far outweigh any individualized issues regarding Class Members.

28 Therefore, this action is appropriate for class certification for settlement

1 purposes, embodying all the hallmarks, both in form and in substance, of class
2 actions routinely certified in this Circuit.

3 **VI. THE SETTLEMENT PROVIDES PROPER NOTICE TO THE**
4 **CLASS**

5 Rule 23(e)(1) states that “[t]he court must direct notice in a reasonable
6 manner to all Class Members who would be bound by a proposed settlement,
7 voluntary dismissal, or compromise.” Notice to the class must be “the best notice
8 that is practicable under the circumstances, including individual notice to all
9 members who can be identified through reasonable effort.” Fed. R. Civ. P.
10 23(c)(2)(B); *see also Amchem Prods., Inc. v. Windsor*, 521 U.S. 591, 617 (1997);
11 *Mullane v. Cen. Hanover Bank & Trust Co.*, 229 U.S. 306, 314 (1950). The notice
12 must contain the following information: (1) the nature of the action; (2) the
13 definition of the class; (3) the class claims, issues, or defenses; (4) that any class
14 member may appear at the fairness hearing through an attorney; (5) that the court
15 will exclude from the class any member who requests exclusion; (6) the time and
16 manner for requesting exclusion; and (7) the binding effect of a judgment on Class
17 Members. Fed. R. Civ. P. 23(c)(2)(B).

18 Where the identity of specific Class Members is not reasonably available,
19 notice by publication is an acceptable method of providing notice. *See In re*
20 *Tableware Antitrust Litig.*, 484 F.Supp.2d at 1080 (citing *Manual for Complex*
21 *Litigation* § 21.311 (4th ed. 2004)); Cal. Civ. Code § 1781 (authorizing notice by
22 publication under the CLRA “if personal notification is unreasonably expensive or it
23 appears that all members of the class cannot be notified personally”). Here, Iovate
24 did not directly sell its Protein Products to Class Members so it does not possess
25 contact information for the Class Members.

26 The primary means of notice in this case will be notice by publication in print
27 format and via the Internet. Class Counsel and Kinsella have determined that
28 internet advertising is the best method to provide targeted notice to the Class, which

1 is comprised of younger and Internet savvy consumers. The advertising will be
2 targeted to consumers who are interested in health, fitness, and exercising. The
3 Internet-based portion of the notice plan calls for targeted Internet banner
4 advertisements running for four weeks on several popular health and fitness
5 websites, including: (1) Men's Health; (2) Men's Fitness; (3) Muscle & Fitness; (4)
6 Muscle & Fitness Hers; and (5) Flex. Targeted notice will also be provided through
7 Facebook to individuals who have expressed an interest in health and fitness. By
8 advertising on these websites, the notice is expected to result in 50 million
9 impressions³ that are targeted to reach the Class Members.

10 In addition to Internet advertising, the notice plan calls for the insertion of
11 quarter-page notices Monday through Thursday for four consecutive weeks in *USA*
12 *Today's* Los Angeles and San Francisco regional editions. This print publication
13 plan satisfies the publication requirements of the CLRA.

14 Plaintiff's counsel will also issue an informational press release over PR
15 Newswire's US1 and National Hispanic newslines. The US1 release will be issued
16 broadly to more than 15,000 media outlets, including newspapers, magazines,
17 national wire services, television, radio, and online media in all 50 states. The
18 Hispanic newswire reaches over 7,000 U.S. Hispanic media contacts including
19 online placement of approximately 100 Hispanic websites nationally.

20 The content of the notice complies with the requirements of Rule 23(c)(2)(B).
21 As seen in both the Long Form and Short Form notices attached to the Settlement
22 Agreement, the notice describes the nature of the action, states the definition of the
23 class, explains the binding effect of the judgment on Class Members, and provides
24

25
26 ³ "Impressions" are defined as the number of times a user was exposed to the
27 advertisement.
28

all of the necessary information for Class Members to appear at the fairness hearing, file a claim, object to the settlement, and/or exclude themselves from the Class.

Accordingly, the Court should approve the proposed notice plan.

VII. THE COURT SHOULD SET A FINAL APPROVAL HEARING SCHEDULE

The last step in the settlement approval process is the final approval hearing, at which the Court may hear all evidence and argument necessary to evaluate the proposed settlement. At that hearing, proponents of the settlement may explain and describe their terms and conditions and offer argument in support of settlement approval. Members of the Class—or their counsel—may be heard in support of or in opposition to the settlement. Plaintiff proposes the following schedule for final approval of the settlement:

Date	Action
Within 30 days after entry of the Order Granting Preliminary Approval	Commencement of Notice to the Class Members (“Notice Date”)
45 days after the Notice Date	Deadline to file Plaintiff’s Motion for Attorneys’ Fees, Costs, and Incentive Award
60 days after the Notice Date	Deadline for Class Members to file a claim, opt-out, or object to the Settlement Agreement and Plaintiff’s Motion for Attorneys’ Fees, Costs, and Incentive Award
75 days after the Notice Date	Deadline to file Plaintiff’s Motion for Final Approval of the Settlement Agreement
75 days after the Notice Date	Deadline for the parties to respond to any objection to the Settlement Agreement and/or Plaintiff’s Motion for Attorneys’ Fees, Costs, and Incentive Award
100 days after the Notice Date	Final approval/fairness hearing

///

VIII. ATTORNEYS' FEES AND COSTS AND ENHANCEMENT

AWARDS

The Settlement Agreement states that Class Counsel may apply to the Court for an award of attorneys' fees and costs in an amount not to exceed twenty-five percent (25%) of the \$2.5 million Non-Reversionary Common Fund (i.e. up to \$625,000) and expenses and verified costs in an amount not to exceed \$15,000.00. (Settlement Agreement, § 9.1.) The Settlement Agreement also allows Plaintiff to apply to the Court for an enhancement award of \$5,000. (Settlement Agreement, § 9.2.) The enhancement award is designed to reward the class representative for his service to the Class, and is consistent with Ninth Circuit precedent that holds enhancement awards cannot be conditioned on class representatives' support for the settlement. *See Radcliffe v. Experian Info. Solutions, Inc.*, 715 F.3d 1157, 1161 (9th Cir. 2013).

The Notice will explain the forthcoming motion for attorneys' fees, costs, and enhancement award so that Class Members will be aware of the proposed requests. The motion for attorneys' fees, costs, and enhancement awards will be filed a reasonable time before the deadline for objections. *See In re Mercury Interactive Corp. Sec. Litig.*, 618 F.3d 988, 995 (9th Cir. 2010) (holding that Class Members should have adequate time to review motion for attorneys' fees before deadline for objections).

///

///

///

///

///

///

///

///

865070.5

1 **IX. CONCLUSION**

2 Based on the foregoing, Plaintiff respectfully requests that the Court grant
3 preliminary approval of the Settlement Agreement, approve the proposed notice
4 plan, and establish a final approval hearing schedule.

5

6 DATED: October 9, 2015

PEARSON, SIMON & WARSHAW, LLP
DANIEL L. WARSHAW
BOBBY POUYA
MATTHEW A. PEARSON
ALEXANDER R. SAFYAN

7

8

9

10

11

By: /s/ Daniel L. Warshaw
DANIEL L. WARSHAW
Attorneys for Plaintiff James Eashoo,
individually and on behalf of all others
similarly situated

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

PEARSON, SIMON & WARSHAW, LLP
15165 VENTURA BOULEVARD, SUITE 400
SHERMAN OAKS, CALIFORNIA 91403